21,280 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Scholtz & Company LLC

Scholtz & Company LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 21,280 shares of the life sciences company’s stock, valued at approximately $2,844,000. Illumina comprises about 1.4% of Scholtz & Company LLC’s holdings, making the stock its 24th biggest position.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Bleakley Financial Group LLC bought a new stake in shares of Illumina in the fourth quarter worth approximately $751,000. Zacks Investment Management purchased a new stake in Illumina in the third quarter worth approximately $2,924,000. Van ECK Associates Corp boosted its holdings in Illumina by 17.5% in the fourth quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock worth $20,347,000 after purchasing an additional 22,718 shares during the last quarter. Strategic Financial Concepts LLC bought a new stake in Illumina in the 4th quarter worth approximately $1,464,000. Finally, Allworth Financial LP raised its stake in Illumina by 720.7% during the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after buying an additional 6,263 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on ILMN. HSBC lowered Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective for the company. in a report on Friday, February 28th. Canaccord Genuity Group cut their price target on Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, March 11th. Morgan Stanley lowered their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Royal Bank of Canada cut their target price on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating for the company in a research report on Wednesday, March 12th. Finally, TD Cowen downgraded shares of Illumina from a “buy” rating to a “hold” rating and decreased their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average price target of $140.90.

Illumina Trading Down 1.2 %

Illumina stock opened at $78.39 on Wednesday. Illumina, Inc. has a 1 year low of $77.54 and a 1 year high of $156.66. The firm’s 50 day moving average price is $100.39 and its 200-day moving average price is $126.13. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The stock has a market cap of $12.42 billion, a P/E ratio of -10.21, a PEG ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.